Summary
Cytodyn Inc (Cytodyn) is a biotechnology company which focuses on clinical development and commercialization of therapeutic monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products under development include PRO 140, Cytofeline and Cytolin. Cytodyn’s PRO 140 is a viral-entry inhibitor intended to protect healthy cells from viral infection which blocks the HIV co-receptor CCR5 on T-cells. Cytofeline, a Anti-LFA-1 antibody is used for the treatment of FIV infection. Cytolin is a mouse monoclonal antibody developed to identify a immune cell called cytotoxic T cell (CTL). Cytodyn is headquartered in Vancouver, Washington, the US.
Cytodyn Inc (CYDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 11
Venture Financing 12
Cytodyn Raises USD2.7 million in Financing Round 12
CytoDyn Raises USD3.3 million in Venture Financing Round 13
Partnerships 13
CytoDyn Amends Research Agreement with Drexel University College of Medicine 13
Licensing Agreements 14
CytoDyn Enters into Licensing Agreement with Lonza Sales 14
Equity Offering 15
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 15
CytoDyn Raises USD1.2 Million in Private Placement of Shares 16
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 17
CytoDyn Raises USD4.3 Million in Private Placement of Shares 18
CytoDyn Raises USD7.3 Million in Private Placement of Shares 19
CytoDyn Raises USD14.5 Million in Private Placement of Units 20
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 20
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 21
CytoDyn Completes Private Placement Of Common Stock For US$3 Million 22
Debt Offering 22
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 22
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 23
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 23
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 24
Cytodyn Inc - Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Apr 11, 2017: CytoDyn appoints new board member 28
Apr 11, 2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 29
Jan 30, 2017: CytoDyn appoints executive chairman 30
Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 31
Jan 20, 2016: CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
List of Tables
Cytodyn Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cytodyn Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 11
Cytodyn Raises USD2.7 million in Financing Round 12
CytoDyn Raises USD3.3 million in Venture Financing Round 13
CytoDyn Amends Research Agreement with Drexel University College of Medicine 13
CytoDyn Enters into Licensing Agreement with Lonza Sales 14
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 15
CytoDyn Raises USD1.2 Million in Private Placement of Shares 16
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 17
CytoDyn Raises USD4.3 Million in Private Placement of Shares 18
CytoDyn Raises USD7.3 Million in Private Placement of Shares 19
CytoDyn Raises USD14.5 Million in Private Placement of Units 20
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 20
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 21
CytoDyn Completes Private Placement Of Common Stock For US$3 Million 22
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 22
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 23
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 23
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 24
Cytodyn Inc, Key Competitors 25
Cytodyn Inc, Key Employees 26
Cytodyn Inc, Subsidiaries 27List of Figures
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
